Vanda Pharmaceuticals (NASDAQ:VNDA): Stifel Nicolaus Keeps “Buy” Rating Today, Has a Target of $44/Share

Investors sentiment increased to 1.8 in 2018 Q3. Its up 0.27, from 1.53 in 2018Q2. It improved, as 11 investors sold Vanda Pharmaceuticals Inc. shares while 35 reduced holdings. 36 funds opened positions while 47 raised stakes. 51.01 million shares or 7.09% more from 47.64 million shares in 2018Q2 were reported.

Dimensional Fund Advsrs Lp reported 259,910 shares stake. 1,750 are owned by Ls Invest Advsr Limited Liability Company. Morgan Stanley holds 520,349 shares or 0% of its portfolio. The New York-based Element Cap Management Lc has invested 0.01% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Cubist Systematic Strategies Limited Company holds 0.09% or 69,211 shares in its portfolio. 9,652 were accumulated by Hightower Limited Liability Co. Moreover, Savings Bank Of Mellon has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). First Quadrant Limited Partnership Ca holds 37,029 shares or 0.02% of its portfolio. Shanda Asset Mgmt Holdg Limited has 44,787 shares. Rothschild & Asset Mngmt Us reported 0.1% stake. Blackrock Inc stated it has 8.85M shares. Bogle Invest Mngmt L P De holds 0.34% or 206,154 shares in its portfolio. Moreover, Tower Research Capital Lc (Trc) has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Sun Life Fin owns 7,871 shares. Dekabank Deutsche Girozentrale stated it has 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Vanda Pharmaceuticals (NASDAQ:VNDA) Rating Reaffirmed

They currently have a $44 PT on Vanda Pharmaceuticals (NASDAQ:VNDA). The target price by Stifel Nicolaus would suggest a potential upside of 62.00 % from the company’s current stock price. This has been revealed to clients and investors in a research report on 11 December.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 6 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals has $52 highest and $26 lowest target. $37.83’s average target is 39.29% above currents $27.16 stock price. Vanda Pharmaceuticals had 8 analyst reports since August 23, 2018 according to SRatingsIntel. The rating was maintained by Citigroup on Tuesday, October 16 with “Buy”. On Friday, September 21 the stock rating was maintained by Oppenheimer with “Outperform”. Cantor Fitzgerald upgraded Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rating on Tuesday, December 4. Cantor Fitzgerald has “Overweight” rating and $43 target. The firm has “Market Outperform” rating given on Thursday, December 6 by JMP Securities. Citigroup maintained it with “Buy” rating and $47 target in Friday, December 7 report.

The stock decreased 5.27% or $1.51 during the last trading session, reaching $27.16. About 1.09M shares traded or 7.90% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 106.26% since December 12, 2017 and is uptrending. It has outperformed by 106.26% the S&P500.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on February, 13. They expect $-0.03 EPS, up 25.00 % or $0.01 from last year’s $-0.04 per share. After $0.13 actual EPS reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -123.08 % negative EPS growth.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $1.43 billion. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It has a 106.93 P/E ratio. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: which released: “Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22% – Nasdaq” on November 16, 2018, also with their article: “Explosion of Latest Clinical Studies and Results Reinvigorating Immunotherapy Market – PRNewswire” published on December 04, 2018, published: “Inovio (INO) to Receive Milestone Payment From AstraZeneca – Nasdaq” on December 05, 2018. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: and their article: “Baker Bros. Advisors 13F for Quarter Ended Sept. 30, 2018 –” published on November 14, 2018 as well as‘s news article titled: “Vanda Pharmaceutical Inc. (VNDA) Has Risen To A New High After Q3 Report – Nasdaq” with publication date: November 08, 2018.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.